Rekha Chaudhary, MD
Hematology & Oncology · West Chester, OHNPI 1982699484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,519 of the $113,180 with a category attached, or 83.5%. 13 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 40.8% of the total. Reporting peaked in 2019 at $34,573 and has fallen 74.6% since, to $8,781 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $1001.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$46K
- Merck$32K
- Regeneron Healthcare Solutions, Inc.$18K
- Sanofi$17K
- Novocure Inc.$227
- Astellas Pharma US Inc$99
- plus $288 from 7 others
Across 53 payments — averaging $13,593 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$668K
- Regeneron$32K
- Genentech, Inc.$19K
- AbbVie$1K
What the payments were for
- Consulting fees$11,90111%
- Speaking & faculty fees$94,51984%
- Travel & lodging$3,5443%
- Food & beverage$3,0983%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 44 | $46,223 |
| Merck | 30 | $31,643 |
| Regeneron Healthcare Solutions, Inc. | 13 | $18,022 |
| Sanofi | 13 | $16,678 |
| Novocure Inc. | 3 | $227 |
| Astellas Pharma US Inc | 1 | $99 |
| Immunocore Limited | 2 | $97 |
| Mayne Pharma Commercial LLC | 1 | $90 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Bristol Myers Squibb | 1 | $19 |
| Novartis | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,180 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 13 | $405,145 |
| EliquisApixaban | 24 | $15,710 |
| Levetiracetam | 18 | $550 |
| Pantoprazole Sodium | 13 | $90 |
| Ondansetron Hcl | 11 | $86 |
| Warfarin Sodium | 12 | $64 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in West Chester
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.